Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 龙浩锋教授 (肿瘤学系) |
| 莫树锦教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.2217/FON.14.314 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/2WOS source URL
其它资讯
摘要Rearrangement of ALK gene has been identified as exerting a potent transforming effect as driver oncogene in patients with non-small-cell lung cancer (NSCLC). Crizotinib is a small-molecule oral inhibitor of ALK, c-Met/HGF receptor and ROS1 receptor kinases. Its efficacy in ALK-rearranged NSCLC has been established. Crizotinib's effect on ROS1 receptor kinases and c-Met with relevance to NSCLC is also actively being explored. Resistance mechanisms such as secondary gatekeeper mutations in ALK gene and activation of other oncogenes have been identified to confer acquired resistance to crizotinib. This article reviews the pharmacological properties of crizotinib, preclinical and clinical results that led to its approval in ALK-positive NSCLC and current directions of clinical research in overcoming crizotinib resistance.
着者Loong HH, Mok K, Leung LKS, Mok TSK
期刊名称Future Oncology
出版年份http://aims.cuhk.edu.hk/converis/portal/Publication/2015
月份1
日期1
卷号11
期次5
出版社Future Medicine
页次735 - 745
国际标準期刊号1479-6694
电子国际标準期刊号1744-8301
语言英式英语
关键词acquired resistance; brain metastases; c-Met; crizotinib; EML4-ALK fusion; non-small-cell lung cancer; ROS1
Web of Science 学科类别Oncology
